FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362594938> ?p ?o ?g. }

• W4362594938 endingPage "578" @default.
• W4362594938 startingPage "578" @default.
• W4362594938 abstract "Abstract Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype accounting for around 15% of all breast cancer patients and is responsible for 30% of breast cancer-related deaths. Although chemotherapy is the mainstay therapy for TNBC, development of resistance significantly reduces patients’ survival. Therefore, there is an urgent need to identify novel and effective treatment strategies to overcome chemoresistance. Recently, we identified hypoxia-induced ECM re-modeler, lysyl oxidase (LOX), a member of LOX family, as a key mediator of chemoresistance in TNBC. In this study, combining a robust screening platform for drug-like molecules and cell-based/recombinant protein assays, we identified bi-thiazole derivatives as novel potent LOX inhibitors. Further structure activity relationship (SAR) analysis resulted in two lead compounds: 6403, a relatively LOX-specific inhibitor, and 6415, a more LOX/LOXL2 dual inhibitor. Both compounds reduced collagen crosslinking and led to chemosensitization in TNBC cell lines in 3D culture and in chemoresistant TNBC PDX organoids. Furthermore, re-analyses of scRNA-Seq data of TNBC patients treated with neo-adjuvant chemotherapy with known chemoresponse or resistance showed that LOX+ cells were enriched upon chemotherapy only in treatment-refractory patients. Importantly, we identified a significant correlation between LOX and the gene sets of Reactive Oxygen Species (ROS) and DNA repair in TNBC patients treated with chemotherapy. Supporting this, increased chemotherapy penetration upon LOX inhibition resulted in elevated ROS levels and DNA damage in cells, leading to inhibition of FAK/Akt survival signaling. The efficacy of 6403 was tested in a chemoresistant TNBC PDX model where combination of doxorubicin with LOX inhibitor overcame doxorubicin resistance with no significant change in body weights. State-of-the-art MALDI-MSI and MP-SHG experiments showed efficient reduction of collagen content and crosslinking, respectively in PDX tumors upon LOX inhibition. Overall, these results show that novel bi-thiazole LOX inhibitors block collagen crosslinking and potentiates chemotherapy-induced ROS-DNA damage axis to overcome chemoresistance in TNBC. Citation Format: Metin Cetin, Ozge Saatci, Abdol-Hossein Rezaeian, Ozge Akbulut, Nageswara Rao Chintada, Harrison Taylor, Breanna Pederson, Ioulia Chatzistamou, Hamed Shateri Najafabadi, Susan Lessner, Peggi Angel, Campbell McInnes, Ozgur Sahin. Novel bi-thiazole LOX inhibitors to overcome chemotherapy resistance in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 578." @default.
• W4362594938 created "2023-04-06" @default.
• W4362594938 creator A5008265767 @default.
• W4362594938 creator A5009324730 @default.
• W4362594938 creator A5009694924 @default.
• W4362594938 creator A5015539963 @default.
• W4362594938 creator A5018611126 @default.
• W4362594938 creator A5026022361 @default.
• W4362594938 creator A5033125510 @default.
• W4362594938 creator A5033383913 @default.
• W4362594938 creator A5037316485 @default.
• W4362594938 creator A5042482830 @default.
• W4362594938 creator A5047393084 @default.
• W4362594938 creator A5054481590 @default.
• W4362594938 creator A5061725145 @default.
• W4362594938 date "2023-04-04" @default.
• W4362594938 modified "2023-09-24" @default.
• W4362594938 title "Abstract 578: Novel bi-thiazole LOX inhibitors to overcome chemotherapy resistance in triple negative breast cancer" @default.
• W4362594938 doi "https://doi.org/10.1158/1538-7445.am2023-578" @default.
• W4362594938 hasPublicationYear "2023" @default.
• W4362594938 type Work @default.
• W4362594938 citedByCount "0" @default.
• W4362594938 crossrefType "journal-article" @default.
• W4362594938 hasAuthorship W4362594938A5008265767 @default.
• W4362594938 hasAuthorship W4362594938A5009324730 @default.
• W4362594938 hasAuthorship W4362594938A5009694924 @default.
• W4362594938 hasAuthorship W4362594938A5015539963 @default.
• W4362594938 hasAuthorship W4362594938A5018611126 @default.
• W4362594938 hasAuthorship W4362594938A5026022361 @default.
• W4362594938 hasAuthorship W4362594938A5033125510 @default.
• W4362594938 hasAuthorship W4362594938A5033383913 @default.
• W4362594938 hasAuthorship W4362594938A5037316485 @default.
• W4362594938 hasAuthorship W4362594938A5042482830 @default.
• W4362594938 hasAuthorship W4362594938A5047393084 @default.
• W4362594938 hasAuthorship W4362594938A5054481590 @default.
• W4362594938 hasAuthorship W4362594938A5061725145 @default.
• W4362594938 hasConcept C121608353 @default.
• W4362594938 hasConcept C126322002 @default.
• W4362594938 hasConcept C143998085 @default.
• W4362594938 hasConcept C181199279 @default.
• W4362594938 hasConcept C185592680 @default.
• W4362594938 hasConcept C193143273 @default.
• W4362594938 hasConcept C2776310068 @default.
• W4362594938 hasConcept C2776694085 @default.
• W4362594938 hasConcept C2780110267 @default.
• W4362594938 hasConcept C2781303535 @default.
• W4362594938 hasConcept C502942594 @default.
• W4362594938 hasConcept C530470458 @default.
• W4362594938 hasConcept C55493867 @default.
• W4362594938 hasConcept C71924100 @default.
• W4362594938 hasConceptScore W4362594938C121608353 @default.
• W4362594938 hasConceptScore W4362594938C126322002 @default.
• W4362594938 hasConceptScore W4362594938C143998085 @default.
• W4362594938 hasConceptScore W4362594938C181199279 @default.
• W4362594938 hasConceptScore W4362594938C185592680 @default.
• W4362594938 hasConceptScore W4362594938C193143273 @default.
• W4362594938 hasConceptScore W4362594938C2776310068 @default.
• W4362594938 hasConceptScore W4362594938C2776694085 @default.
• W4362594938 hasConceptScore W4362594938C2780110267 @default.
• W4362594938 hasConceptScore W4362594938C2781303535 @default.
• W4362594938 hasConceptScore W4362594938C502942594 @default.
• W4362594938 hasConceptScore W4362594938C530470458 @default.
• W4362594938 hasConceptScore W4362594938C55493867 @default.
• W4362594938 hasConceptScore W4362594938C71924100 @default.
• W4362594938 hasIssue "7_Supplement" @default.
• W4362594938 hasLocation W43625949381 @default.
• W4362594938 hasOpenAccess W4362594938 @default.
• W4362594938 hasPrimaryLocation W43625949381 @default.
• W4362594938 hasRelatedWork W1563147852 @default.
• W4362594938 hasRelatedWork W1966181922 @default.
• W4362594938 hasRelatedWork W2379009234 @default.
• W4362594938 hasRelatedWork W2388730008 @default.
• W4362594938 hasRelatedWork W2534174115 @default.
• W4362594938 hasRelatedWork W2554176272 @default.
• W4362594938 hasRelatedWork W2888577064 @default.
• W4362594938 hasRelatedWork W3031200888 @default.
• W4362594938 hasRelatedWork W3135230498 @default.
• W4362594938 hasRelatedWork W4306163962 @default.
• W4362594938 hasVolume "83" @default.
• W4362594938 isParatext "false" @default.
• W4362594938 isRetracted "false" @default.
• W4362594938 workType "article" @default.